Profitability
This table compares ObsEva and Ceapro’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ObsEva | N/A | -416.36% | -92.01% |
| Ceapro | -69.60% | -20.30% | -18.07% |
Institutional & Insider Ownership
17.5% of ObsEva shares are owned by institutional investors. 14.4% of ObsEva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares ObsEva and Ceapro”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ObsEva | N/A | N/A | -$58.38 million | ($0.92) | N/A |
| Ceapro | $7.14 million | 1.86 | -$3.49 million | ($0.06) | -2.83 |
Ceapro has higher revenue and earnings than ObsEva. Ceapro is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
ObsEva has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Ceapro has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500.
Summary
Ceapro beats ObsEva on 6 of the 10 factors compared between the two stocks.
About ObsEva
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.
About Ceapro
Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.
